. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: J Invest Dermatol. 2019 Jul 19;140(1):85–93.e2. doi: 10.1016/j.jid.2019.07.679

Table 2.

Changes in Psoriasis Activity by Treatment Group During Trial Period

	Ustekinumab (n=22)	Placebo (n=19)	Combined (n=39)
Changes between	Baseline and Week 12		Baseline and EOS
PASI75^*	0.773 (0.546, 0.922)	0.105 (0.013, 0.331)	0.718 (0.551, 0.850)
PASI90^*	0.409 (0.207, 0.637)	0 (0, 0.177)	0.487 (0.24, 0.652)
PGA (clear/almost clear)^*	0.636 (0.407, 0.828)	0.105 (0.013, 0.331)	0.462 (0.301, 0.628)
	Change compared with placebo (n=41)
PASI75^**	−0.668 (<0.001)^***	-
PASI90^**	−0.409 (0.002)^***	-
PGA^**	−0.531 (<0.001)^***	-

Proportion (95% CI) PASI: psoriasis area severity index score; PGA: physician global assessment

^**

Difference of proportions (P value)

^***

Statistically significant findings